Table 1.
Prevalence of pre-antiretroviral treatment HIV drug resistance mutations detected by OLA in each antiretroviral-naïve adult by cohort year.*
| Mutant Codon | 2006 (N=386) | 2014 (N=567) | Total (N=953) |
|---|---|---|---|
| K103N | 8 (2.1%) | 30 (5.3%) | 38 (4.0%) |
| Y181C | 1 (0.3%) | 8 (1.4%) | 10 (0.9%) |
| G190A | 0 (0%) | 3 (0.5%) | 3 (0.3%) |
| M184V | 0 (0%) | 2 (0.4%) | 2 (0.2%) |
| K65 | 0 (0%) | 2 (0.4%) | 2 (0.2%) |
| K103N + Y181C | 0 (0%) | 1 (0.2%) | 1 (0.1%) |
| K103N + G190A | 1 (0.3%) | 5 (0.9%) | 6 (0.6%) |
| K103N + M184V | 1 (0.3%) | 3 (0.5%) | 4 (0.4%) |
| Y181C + G190A | 1 (0.3%) | 0 (0%) | 1 (0.1%) |
| Y181C + M184V | 0 (0%) | 1 (0.2%) | 1 (0.1%) |
| Y181C + K65R | 0 (0%) | 1 (0.2%) | 1 (0.1%) |
| G190A + M184V | 0 (0%) | 1 (0.2%) | 1 (0.1%) |
| K103N + Y181C + M184V | 2 (0.5%) | 2 (0.4%) | 4 (0.4%) |
| K103N + G190A + Y181C | 1 (0.3%) | 0 (0%) | 1 (0.1%) |
| Y181C + M184V +K65R | 0 (0%) | 2 (0.4%) | 2 (0.2%) |
| G190A + M184V + K65R | 0 (0%) | 1 (0.2%) | 1 (0.1%) |
| Total | 15 *(3.9%) | 62 *(10.9%) | 77 (8.1%) |
*
Poisson regression with robust standard error estimates comparing 2014 to 2006 found an unadjusted prevalence ratio of 2.81 (95% CI, 1.62, 4.87; p<0.001).